170570-75-9 : Celecoxib Bromo Impurity

It is a selective cyclooxygenase-2 inhibitor, By inhibiting prostaglandin synthesis non-steroidal anti-inflammatory drugs cause mucosal damage and ulceration. Celecoxib poses less of an ulceration risk than other NSAIDS, owing to its decreased effect on gastric mucosal prostaglandin synthesis when compared to placebo, also exerts anticancer effects by binding to the cadherin-11 protein, which is involved in the progression of tumors and inhibiting the 3 phosphoinositide-dependent kinase-1 signaling mechanism, which is used to treat osteoarthritis, rheumatoid arthritis, and to reduce polyps in familial adenomatous polyposis.